Pharmacology of a potential anti-Parkinson agent: tigloidine.
D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology*; D001341:Autonomic Nervous System / Q000187:drug effects; D001965:Bromides / Q000494:pharmacology; D002415:Cats; D002490:Central Nervous System / Q000187:drug effects; D004285:Dogs; D004336:Drug Antagonism; D004357:Drug Synergism; D051379:Mice; D010276:Parasympatholytics / Q000494:pharmacology*; D010830:Physostigmine / Q000494:pharmacology; D051381:Rats; D013045:Species Specificity; D014203:Tremorine / Q000494:pharmacology
D001965:Bromides; D010276:Parasympatholytics; D001285:Atropine; D010830:Physostigmine; D000661:Amphetamine; D014203:Tremorine